Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers
The anticancer activities of Withaferin-A (Wi-A) and Withanone (Wi-N) from Ashwagandha and Caffeic Acid Phenethyl Ester (CAPE) from honeybee propolis have been well documented. Here, we examined the binding potential of these natural compounds to inhibit the constitutive phosphorylation of epidermal...
| Prif Awduron: | , , , , |
|---|---|
| Fformat: | Erthygl |
| Iaith: | English |
| Cyhoeddwyd: |
MDPI AG
2021-01-01
|
| Cyfres: | Biomolecules |
| Pynciau: | |
| Mynediad Ar-lein: | https://www.mdpi.com/2218-273X/11/2/160 |
| _version_ | 1827597817470779392 |
|---|---|
| author | Vidhi Malik Vipul Kumar Sunil C. Kaul Renu Wadhwa Durai Sundar |
| author_facet | Vidhi Malik Vipul Kumar Sunil C. Kaul Renu Wadhwa Durai Sundar |
| author_sort | Vidhi Malik |
| collection | DOAJ |
| description | The anticancer activities of Withaferin-A (Wi-A) and Withanone (Wi-N) from Ashwagandha and Caffeic Acid Phenethyl Ester (CAPE) from honeybee propolis have been well documented. Here, we examined the binding potential of these natural compounds to inhibit the constitutive phosphorylation of epidermal growth factor receptors (EGFRs). Exon 20 insertion mutants of EGFR, which show resistance to various FDA approved drugs and are linked to poor prognosis of lung cancer patients, were the primary focus of this study. Apart from exon 20 insertion mutants, the potential of natural compounds to serve as ATP competitive inhibitors of wildtype protein and other common mutants of EGFR, namely L858R and exon19del, were also examined. The potential of natural compounds was compared to the positive controls such as erlotinib, TAS6417 and poziotinib. Similar to known inhibitors, Wi-A and Wi-N could displace and binds at the ATP orthosteric site of exon19del, L858R and exon20, while CAPE was limited to wildtype EGFR and exon 20 insertion mutants only. Moreover, the binding free energy of the natural drugs against EGFRs was also comparable to the positive controls. This computational study suggests that Wi-A and Wi-N have potential against multiple mutated EGFRs, warranting further <i>in vitro</i> and <i>in vivo</i> experiments. |
| first_indexed | 2024-03-09T03:39:41Z |
| format | Article |
| id | doaj.art-ab0968a8b51b4db890a9f6d88e10ded4 |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-09T03:39:41Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-ab0968a8b51b4db890a9f6d88e10ded42023-12-03T14:43:46ZengMDPI AGBiomolecules2218-273X2021-01-0111216010.3390/biom11020160Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung CancersVidhi Malik0Vipul Kumar1Sunil C. Kaul2Renu Wadhwa3Durai Sundar4DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), Department of Biochemical Engineering & Biotechnology, Indian Institute of Technology (IIT) Delhi, Hauz Khas, New Delhi 110 016, IndiaDBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), Department of Biochemical Engineering & Biotechnology, Indian Institute of Technology (IIT) Delhi, Hauz Khas, New Delhi 110 016, IndiaAIST-INDIA DAILAB, DBT-AIST International Center for Translational & Environmental Research (DAICENTER), National Institute of Advanced Industrial Science & Technology (AIST), Tsukuba 305-8565, JapanAIST-INDIA DAILAB, DBT-AIST International Center for Translational & Environmental Research (DAICENTER), National Institute of Advanced Industrial Science & Technology (AIST), Tsukuba 305-8565, JapanDBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), Department of Biochemical Engineering & Biotechnology, Indian Institute of Technology (IIT) Delhi, Hauz Khas, New Delhi 110 016, IndiaThe anticancer activities of Withaferin-A (Wi-A) and Withanone (Wi-N) from Ashwagandha and Caffeic Acid Phenethyl Ester (CAPE) from honeybee propolis have been well documented. Here, we examined the binding potential of these natural compounds to inhibit the constitutive phosphorylation of epidermal growth factor receptors (EGFRs). Exon 20 insertion mutants of EGFR, which show resistance to various FDA approved drugs and are linked to poor prognosis of lung cancer patients, were the primary focus of this study. Apart from exon 20 insertion mutants, the potential of natural compounds to serve as ATP competitive inhibitors of wildtype protein and other common mutants of EGFR, namely L858R and exon19del, were also examined. The potential of natural compounds was compared to the positive controls such as erlotinib, TAS6417 and poziotinib. Similar to known inhibitors, Wi-A and Wi-N could displace and binds at the ATP orthosteric site of exon19del, L858R and exon20, while CAPE was limited to wildtype EGFR and exon 20 insertion mutants only. Moreover, the binding free energy of the natural drugs against EGFRs was also comparable to the positive controls. This computational study suggests that Wi-A and Wi-N have potential against multiple mutated EGFRs, warranting further <i>in vitro</i> and <i>in vivo</i> experiments.https://www.mdpi.com/2218-273X/11/2/160EGFRexon 20 insertion mutationsWithaferin AWithanoneCaffeic Acid Phenethyl EsterATP competitive inhibitors |
| spellingShingle | Vidhi Malik Vipul Kumar Sunil C. Kaul Renu Wadhwa Durai Sundar Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers Biomolecules EGFR exon 20 insertion mutations Withaferin A Withanone Caffeic Acid Phenethyl Ester ATP competitive inhibitors |
| title | Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers |
| title_full | Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers |
| title_fullStr | Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers |
| title_full_unstemmed | Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers |
| title_short | Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers |
| title_sort | computational insights into the potential of withaferin a withanone and caffeic acid phenethyl ester for treatment of aberrant egfr driven lung cancers |
| topic | EGFR exon 20 insertion mutations Withaferin A Withanone Caffeic Acid Phenethyl Ester ATP competitive inhibitors |
| url | https://www.mdpi.com/2218-273X/11/2/160 |
| work_keys_str_mv | AT vidhimalik computationalinsightsintothepotentialofwithaferinawithanoneandcaffeicacidphenethylesterfortreatmentofaberrantegfrdrivenlungcancers AT vipulkumar computationalinsightsintothepotentialofwithaferinawithanoneandcaffeicacidphenethylesterfortreatmentofaberrantegfrdrivenlungcancers AT sunilckaul computationalinsightsintothepotentialofwithaferinawithanoneandcaffeicacidphenethylesterfortreatmentofaberrantegfrdrivenlungcancers AT renuwadhwa computationalinsightsintothepotentialofwithaferinawithanoneandcaffeicacidphenethylesterfortreatmentofaberrantegfrdrivenlungcancers AT duraisundar computationalinsightsintothepotentialofwithaferinawithanoneandcaffeicacidphenethylesterfortreatmentofaberrantegfrdrivenlungcancers |